ASCO GU 2021 Prostate Cancer Videos

HHV-8 Positive Clinically Advanced mCRPC & Genomic Landscape of CDK12 Mutated mCRPC - Petros Grivas

Advancing Knowledge About The Treatment of Advanced Prostate Cancer, Highlights from GU ASCO 2021 - Praful Ravi

Associations of circulating cell-free DNA (cfDNA) and clinical outcomes in metastatic castrate-resistant prostate cancer (mCRPC): A Discussion on the Data - Daniel Shevrin

Cabazitaxel is Active in Men with mCRPC with DDR Alterations - Karim Fizazi and Mihaela Aldea

Talazoparib Monotherapy in Men with DNA Damage Response Alterations (TALAPRO-1) - Celestia Higano

Baseline Pathogenic Mutations in Metastatic Castration-Resistant Prostate Cancer Patients Being Treated with High-Dose Testosterone - Oliver Sartor

Landscape of Circulating Tumor DNA Abnormalities in Advanced Prostate Cancer: Distinctions Between African-American and Caucasians - Pedro Barata

177 Lu-PSMA-617 Offers a Promising Treatment for Men with Progressing mCRPC. - Declan Murphy & Michael Hofman

The Modifiers That Impact Response to the PARP Inhibitor Rucaparib from TRITON2 - Wassim Abida

PROSPER Trial Demonstrates the Relationship Between the Degree of PSA Decline and Survival Outcomes - Cora Sternberg

Genomics Guide Treatment Decisions in Post Prostatectomy Patients - Ashley Ross

Radium-223 plus Enzalutamide vs Enzalutamide Alone in Metastatic Castration-Resistant Prostate Cancer - Benjamin Maughan

Evaluating Circulating Tumor Cells in Patients on the CARD Trial - Eleni Efstathiou

mCSPC Practice Patterns in the Veterans Health System – Stephen Freedland & Scott Tagawa

PSMA-Directed CAR-T First-in-Human Trial in Metastatic Castration-Resistant Prostate Cancer (mCRPC) - Vivek Narayan

Androgen Annihilation with Abiraterone and Apalutamide in Chemo-Naïve mCRPC - Final Results from ACIS- Dana Rathkopf & Fred Saad

Biological Signatures of Patients with Long-Term Responses to Apalutamide and Placebo in Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC)- Felix Feng

The Combination of Pembrolizumab and Radium-223 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) - Atish Choudhury

Biomarker Analysis from a Randomized Study of Olaparib With or Without Cediranib in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC)- Rana Mckay

Phase I RAMP Study Evaluating the Combination of Enzalutamide and Rucaparib in mCRPC - Arpit Rao

Impact of Concomitant Prostate Cancer Therapy of Relugolix in Men with Advanced Prostate Cancer - Daniel J. George

IPATential150 Trial in Metastatic Castration-Resistant Prostate Cancer (mCRPC) - Cora Sternberg

Nivolumab Plus Docetaxel for Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer from CheckMate 9KD Arm B, - Karim Fizazi

Sequential Radium-223 Treatment of mCRPC That Progressed After First-Line Novel Antihormonal Therapy, A Real-World Clinical Outcomes Study - Oliver Sartor

Comparing Lutetium-PSMA Vs. Cabazitaxel in Progressive Metastatic Castration Resistant Prostate Cancer (mCRPC) - Thera-P Trial - Michael Hofman